APO Research
Talk to an analyst

APO RESEARCH · REPORT

Urinary Tract Infection Medications

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Urinary Tract Infection Medications Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

28 December 2025199 pages

Choose your research edition.

Industry ResearchUrinary Tract Infection Medications Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Urinary Tract Infection Medications Industry Growth and Trends Forecast to 2032119 pages · $3,450 USDMarket StructureGlobal Urinary Tract Infection Medications Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Urinary Tract Infection Medications Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Urinary Tract Infection Medications Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Urinary Tract Infection Medications market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Urinary Tract Infection Medications is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Urinary Tract Infection Medications is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Urinary Tract Infection Medications is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Urinary Tract Infection Medications is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Urinary Tract Infection Medications include Allecra Therapeutic, Bayer AG, Cipla Inc., Eli Lily Company, GlaxoSmithKline plc, MEDICE, Merck & Co. Inc., Novartis Ag and Novo Nordisk A/S, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Urinary Tract Infection Medications market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Urinary Tract Infection Medications and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Urinary Tract Infection Medications sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Urinary Tract Infection Medications market size, projected growth trends, production technologies, key applications, and end-use industries.

Urinary Tract Infection Medications Segment by Company

Allecra Therapeutic

Bayer AG

Cipla Inc.

Eli Lily Company

GlaxoSmithKline plc

MEDICE

Merck & Co. Inc.

Novartis Ag

Novo Nordisk A/S

Utility Therapeutics

Northeast Pharmaceuticals

Guangxi Qingzhipin Pharmaceutical Co., Ltd.

Pfizer Inc.

Teva Pharmaceuticals

Whiteson Pharma

Urinary Tract Infection Medications Segment by Type

Cephalosporins

Penicillins

Quinolones

Sulfonamides

Furans

Others

Urinary Tract Infection Medications Segment by Application

Online Pharmacy

Hospital

Clinic

Others

Urinary Tract Infection Medications Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Urinary Tract Infection Medications market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Urinary Tract Infection Medications and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Urinary Tract Infection Medications.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Urinary Tract Infection Medications market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Urinary Tract Infection Medications manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Urinary Tract Infection Medications in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Urinary Tract Infection Medications in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Urinary Tract Infection Medications Industry Trends Table 2. Urinary Tract Infection Medications Industry Drivers Table 3. Urinary Tract Infection Medications Industry Opportunities and Challenges Table 4. Urinary Tract Infection Medications Industry Restraints Table 5. Global Urinary Tract Infection Medications Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Urinary Tract Infection Medications Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Urinary Tract Infection Medications Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Urinary Tract Infection Medications Sales Market Share by Manufacturers Table 9. Global Urinary Tract Infection Medications Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Urinary Tract Infection Medications Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Urinary Tract Infection Medications Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Urinary Tract Infection Medications Manufacturers, Product Type & Application Table 13. Global Urinary Tract Infection Medications Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Urinary Tract Infection Medications by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Cephalosporins Table 17. Major Manufacturers of Penicillins Table 18. Major Manufacturers of Quinolones Table 19. Major Manufacturers of Sulfonamides Table 20. Major Manufacturers of Furans Table 21. Major Manufacturers of Others Table 22. Global Urinary Tract Infection Medications Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Urinary Tract Infection Medications Sales by Type (2021-2026) & (K Units) Table 24. Global Urinary Tract Infection Medications Sales by Type (2027-2032) & (K Units) Table 25. Global Urinary Tract Infection Medications Sales Market Share by Type (2021-2026) Table 26. Global Urinary Tract Infection Medications Sales Market Share by Type (2027-2032) Table 27. Global Urinary Tract Infection Medications Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 28. Global Urinary Tract Infection Medications Revenue by Type (2021-2026) & (K Units) Table 29. Global Urinary Tract Infection Medications Revenue by Type (2027-2032) & (K Units) Table 30. Global Urinary Tract Infection Medications Revenue Market Share by Type (2021-2026) Table 31. Global Urinary Tract Infection Medications Revenue Market Share by Type (2027-2032) Table 32. Major Manufacturers of Online Pharmacy Table 33. Major Manufacturers of Hospital Table 34. Major Manufacturers of Clinic Table 35. Major Manufacturers of Others Table 36. Global Urinary Tract Infection Medications Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Urinary Tract Infection Medications Sales by Application (2021-2026) & (K Units) Table 38. Global Urinary Tract Infection Medications Sales by Application (2027-2032) & (K Units) Table 39. Global Urinary Tract Infection Medications Sales Market Share by Application (2021-2026) Table 40. Global Urinary Tract Infection Medications Sales Market Share by Application (2027-2032) Table 41. Global Urinary Tract Infection Medications Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 42. Global Urinary Tract Infection Medications Revenue by Application (2021-2026) & (K Units) Table 43. Global Urinary Tract Infection Medications Revenue by Application (2027-2032) & (K Units) Table 44. Global Urinary Tract Infection Medications Revenue Market Share by Application (2021-2026) Table 45. Global Urinary Tract Infection Medications Revenue Market Share by Application (2027-2032) Table 46. Global Urinary Tract Infection Medications Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 47. Global Urinary Tract Infection Medications Sales by Region (2021-2026) & (K Units) Table 48. Global Urinary Tract Infection Medications Sales Market Share by Region (2021-2026) Table 49. Global Urinary Tract Infection Medications Sales Forecasted by Region (2027-2032) & (K Units) Table 50. Global Urinary Tract Infection Medications Sales Forecasted Market Share by Region (2027-2032) Table 51. North America Urinary Tract Infection Medications Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. North America Urinary Tract Infection Medications Sales by Country (2021-2026) & (K Units) Table 53. North America Urinary Tract Infection Medications Sales by Country (2027-2032) & (K Units) Table 54. Europe Urinary Tract Infection Medications Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Europe Urinary Tract Infection Medications Sales by Country (2021-2026) & (K Units) Table 56. Europe Urinary Tract Infection Medications Sales by Country (2027-2032) & (K Units) Table 57. Asia Pacific Urinary Tract Infection Medications Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Asia Pacific Urinary Tract Infection Medications Sales by Country (2021-2026) & (K Units) Table 59. Asia Pacific Urinary Tract Infection Medications Sales by Country (2027-2032) & (K Units) Table 60. South America, Middle East and Africa Urinary Tract Infection Medications Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 61. South America, Middle East and Africa Urinary Tract Infection Medications Sales by Country (2021-2026) & (K Units) Table 62. South America, Middle East and Africa Urinary Tract Infection Medications Sales by Country (2027-2032) & (K Units) Table 63. Global Urinary Tract Infection Medications Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 64. Global Urinary Tract Infection Medications Revenue by Region (2021-2026) & (US$ Million) Table 65. Global Urinary Tract Infection Medications Revenue by Region (2027-2032) & (US$ Million) Table 66. Global Urinary Tract Infection Medications Revenue Market Share by Region (2021-2026) Table 67. Global Urinary Tract Infection Medications Revenue Market Share by Region (2027-2032) Table 68. Allecra Therapeutic Company Information Table 69. Allecra Therapeutic Business Overview Table 70. Allecra Therapeutic Urinary Tract Infection Medications Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Allecra Therapeutic Urinary Tract Infection Medications Product Portfolio Table 72. Allecra Therapeutic Recent Development Table 73. Bayer AG Company Information Table 74. Bayer AG Business Overview Table 75. Bayer AG Urinary Tract Infection Medications Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Bayer AG Urinary Tract Infection Medications Product Portfolio Table 77. Bayer AG Recent Development Table 78. Cipla Inc. Company Information Table 79. Cipla Inc. Business Overview Table 80. Cipla Inc. Urinary Tract Infection Medications Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Cipla Inc. Urinary Tract Infection Medications Product Portfolio Table 82. Cipla Inc. Recent Development Table 83. Eli Lily Company Company Information Table 84. Eli Lily Company Business Overview Table 85. Eli Lily Company Urinary Tract Infection Medications Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Eli Lily Company Urinary Tract Infection Medications Product Portfolio Table 87. Eli Lily Company Recent Development Table 88. GlaxoSmithKline plc Company Information Table 89. GlaxoSmithKline plc Business Overview Table 90. GlaxoSmithKline plc Urinary Tract Infection Medications Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. GlaxoSmithKline plc Urinary Tract Infection Medications Product Portfolio Table 92. GlaxoSmithKline plc Recent Development Table 93. MEDICE Company Information Table 94. MEDICE Business Overview Table 95. MEDICE Urinary Tract Infection Medications Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. MEDICE Urinary Tract Infection Medications Product Portfolio Table 97. MEDICE Recent Development Table 98. Merck & Co. Inc. Company Information Table 99. Merck & Co. Inc. Business Overview Table 100. Merck & Co. Inc. Urinary Tract Infection Medications Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Merck & Co. Inc. Urinary Tract Infection Medications Product Portfolio Table 102. Merck & Co. Inc. Recent Development Table 103. Novartis Ag Company Information Table 104. Novartis Ag Business Overview Table 105. Novartis Ag Urinary Tract Infection Medications Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Novartis Ag Urinary Tract Infection Medications Product Portfolio Table 107. Novartis Ag Recent Development Table 108. Novo Nordisk A/S Company Information Table 109. Novo Nordisk A/S Business Overview Table 110. Novo Nordisk A/S Urinary Tract Infection Medications Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Novo Nordisk A/S Urinary Tract Infection Medications Product Portfolio Table 112. Novo Nordisk A/S Recent Development Table 113. Utility Therapeutics Company Information Table 114. Utility Therapeutics Business Overview Table 115. Utility Therapeutics Urinary Tract Infection Medications Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Utility Therapeutics Urinary Tract Infection Medications Product Portfolio Table 117. Utility Therapeutics Recent Development Table 118. Northeast Pharmaceuticals Company Information Table 119. Northeast Pharmaceuticals Business Overview Table 120. Northeast Pharmaceuticals Urinary Tract Infection Medications Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. Northeast Pharmaceuticals Urinary Tract Infection Medications Product Portfolio Table 122. Northeast Pharmaceuticals Recent Development Table 123. Guangxi Qingzhipin Pharmaceutical Co., Ltd. Company Information Table 124. Guangxi Qingzhipin Pharmaceutical Co., Ltd. Business Overview Table 125. Guangxi Qingzhipin Pharmaceutical Co., Ltd. Urinary Tract Infection Medications Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. Guangxi Qingzhipin Pharmaceutical Co., Ltd. Urinary Tract Infection Medications Product Portfolio Table 127. Guangxi Qingzhipin Pharmaceutical Co., Ltd. Recent Development Table 128. Pfizer Inc. Company Information Table 129. Pfizer Inc. Business Overview Table 130. Pfizer Inc. Urinary Tract Infection Medications Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 131. Pfizer Inc. Urinary Tract Infection Medications Product Portfolio Table 132. Pfizer Inc. Recent Development Table 133. Teva Pharmaceuticals Company Information Table 134. Teva Pharmaceuticals Business Overview Table 135. Teva Pharmaceuticals Urinary Tract Infection Medications Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 136. Teva Pharmaceuticals Urinary Tract Infection Medications Product Portfolio Table 137. Teva Pharmaceuticals Recent Development Table 138. Whiteson Pharma Company Information Table 139. Whiteson Pharma Business Overview Table 140. Whiteson Pharma Urinary Tract Infection Medications Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 141. Whiteson Pharma Urinary Tract Infection Medications Product Portfolio Table 142. Whiteson Pharma Recent Development Table 143. Key Raw Materials Table 144. Raw Materials Key Suppliers Table 145. Urinary Tract Infection Medications Distributors List Table 146. Urinary Tract Infection Medications Customers List Table 147. Research Programs/Design for This Report Table 148. Authors List of This Report Table 149. Secondary Sources Table 150. Primary Sources List of Figures Figure 1. Urinary Tract Infection Medications Product Image Figure 2. Global Urinary Tract Infection Medications Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Urinary Tract Infection Medications Market Size (2021-2032) & (US$ Million) Figure 4. Global Urinary Tract Infection Medications Sales (2021-2032) & (K Units) Figure 5. Global Urinary Tract Infection Medications Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Urinary Tract Infection Medications Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Cephalosporins Image Figure 9. Penicillins Image Figure 10. Quinolones Image Figure 11. Sulfonamides Image Figure 12. Furans Image Figure 13. Others Image Figure 14. Global Urinary Tract Infection Medications Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Urinary Tract Infection Medications Sales Market Share 2021 VS 2025 VS 2032 Figure 16. Global Urinary Tract Infection Medications Sales Market Share by Type (2021-2032) Figure 17. Global Urinary Tract Infection Medications Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 18. Global Urinary Tract Infection Medications Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Urinary Tract Infection Medications Revenue Market Share by Type (2021-2032) Figure 20. Online Pharmacy Image Figure 21. Hospital Image Figure 22. Clinic Image Figure 23. Others Image Figure 24. Global Urinary Tract Infection Medications Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Urinary Tract Infection Medications Sales Market Share 2021 VS 2025 VS 2032 Figure 26. Global Urinary Tract Infection Medications Sales Market Share by Application (2021-2032) Figure 27. Global Urinary Tract Infection Medications Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 28. Global Urinary Tract Infection Medications Revenue Market Share 2021 VS 2025 VS 2032 Figure 29. Global Urinary Tract Infection Medications Revenue Market Share by Application (2021-2032) Figure 30. North America Urinary Tract Infection Medications Sales and Growth Rate (2021-2032) & (K Units) Figure 31. North America Urinary Tract Infection Medications Sales Market Share by Country (2021-2032) Figure 32. U.S. Urinary Tract Infection Medications Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Canada Urinary Tract Infection Medications Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Mexico Urinary Tract Infection Medications Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Europe Urinary Tract Infection Medications Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Europe Urinary Tract Infection Medications Sales Market Share by Country (2021-2032) Figure 37. Germany Urinary Tract Infection Medications Sales and Growth Rate (2021-2032) & (K Units) Figure 38. France Urinary Tract Infection Medications Sales and Growth Rate (2021-2032) & (K Units) Figure 39. U.K. Urinary Tract Infection Medications Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Italy Urinary Tract Infection Medications Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Netherlands Urinary Tract Infection Medications Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Asia Pacific Urinary Tract Infection Medications Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Asia Pacific Urinary Tract Infection Medications Sales Market Share by Country (2021-2032) Figure 44. China Urinary Tract Infection Medications Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Japan Urinary Tract Infection Medications Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South Korea Urinary Tract Infection Medications Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Southeast Asia Urinary Tract Infection Medications Sales and Growth Rate (2021-2032) & (K Units) Figure 48. India Urinary Tract Infection Medications Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Australia Urinary Tract Infection Medications Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South America, Middle East and Africa Urinary Tract Infection Medications Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South America, Middle East and Africa Urinary Tract Infection Medications Sales Market Share by Country (2021-2032) Figure 52. Brazil Urinary Tract Infection Medications Sales and Growth Rate (2021-2032) & (K Units) Figure 53. South Africa Urinary Tract Infection Medications Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Saudi Arabia Urinary Tract Infection Medications Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Turkey Urinary Tract Infection Medications Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Argentina Urinary Tract Infection Medications Sales and Growth Rate (2021-2032) & (K Units) Figure 57. UAE Urinary Tract Infection Medications Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Egypt Urinary Tract Infection Medications Sales and Growth Rate (2021-2032) & (K Units) Figure 59. Chile Urinary Tract Infection Medications Sales and Growth Rate (2021-2032) & (K Units) Figure 60. Global Urinary Tract Infection Medications Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 61. Global Urinary Tract Infection Medications Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 62. North America Urinary Tract Infection Medications Revenue (2021-2032) & (US$ Million) Figure 63. North America Urinary Tract Infection Medications Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Europe Urinary Tract Infection Medications Revenue (2021-2032) & (US$ Million) Figure 65. Europe Urinary Tract Infection Medications Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Asia-Pacific Urinary Tract Infection Medications Revenue (2021-2032) & (US$ Million) Figure 67. Asia-Pacific Urinary Tract Infection Medications Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. South America, Middle East and Africa Urinary Tract Infection Medications Revenue (2021-2032) & (US$ Million) Figure 69. South America, Middle East and Africa Urinary Tract Infection Medications Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 70. Urinary Tract Infection Medications Value Chain Figure 71. Manufacturing Cost Structure Figure 72. Urinary Tract Infection Medications Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Cephalosporins
  • Penicillins
  • Quinolones
  • Sulfonamides
  • Furans
  • Others
Applications
  • Online Pharmacy
  • Hospital
  • Clinic
  • Others
Companies covered
  • Allecra Therapeutic
  • Bayer AG
  • Cipla Inc.
  • Eli Lily Company
  • GlaxoSmithKline plc
  • MEDICE
  • Merck & Co. Inc.
  • Novartis Ag
  • Novo Nordisk A/S
  • Utility Therapeutics
  • Northeast Pharmaceuticals
  • Guangxi Qingzhipin Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Teva Pharmaceuticals
  • Whiteson Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Urinary Tract Infection Medications Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Urinary Tract Infection Medications Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Urinary Tract Infection Medications Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Urinary Tract Infection Medications Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Urinary Tract Infection Medications Market Dynamics
  1. 2.1 Urinary Tract Infection Medications Industry Trends
  2. 2.2 Urinary Tract Infection Medications Industry Drivers
  3. 2.3 Urinary Tract Infection Medications Industry Opportunities and Challenges
  4. 2.4 Urinary Tract Infection Medications Industry Restraints
3 Urinary Tract Infection Medications Market by Manufacturers
  1. 3.1 Global Urinary Tract Infection Medications Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Urinary Tract Infection Medications Sales by Manufacturers (2021-2026)
  3. 3.3 Global Urinary Tract Infection Medications Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Urinary Tract Infection Medications Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Urinary Tract Infection Medications Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Urinary Tract Infection Medications Manufacturers, Product Type & Application
  7. 3.7 Global Urinary Tract Infection Medications Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Urinary Tract Infection Medications Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Urinary Tract Infection Medications Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Urinary Tract Infection Medications Tier 1, Tier 2, and Tier 3
4 Urinary Tract Infection Medications Market by Type
  1. 4.1 Urinary Tract Infection Medications Type Introduction
  2. 4.1.1 Cephalosporins
  3. 4.1.2 Penicillins
  4. 4.1.3 Quinolones
  5. 4.1.4 Sulfonamides
  6. 4.1.5 Furans
  7. 4.1.6 Others
  8. 4.2 Global Urinary Tract Infection Medications Sales by Type
  9. 4.2.1 Global Urinary Tract Infection Medications Sales by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Urinary Tract Infection Medications Sales by Type (2021-2032)
  11. 4.2.3 Global Urinary Tract Infection Medications Sales Market Share by Type (2021-2032)
  12. 4.3 Global Urinary Tract Infection Medications Revenue by Type
  13. 4.3.1 Global Urinary Tract Infection Medications Revenue by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Urinary Tract Infection Medications Revenue by Type (2021-2032)
  15. 4.3.3 Global Urinary Tract Infection Medications Revenue Market Share by Type (2021-2032)
5 Urinary Tract Infection Medications Market by Application
  1. 5.1 Urinary Tract Infection Medications Application Introduction
  2. 5.1.1 Online Pharmacy
  3. 5.1.2 Hospital
  4. 5.1.3 Clinic
  5. 5.1.4 Others
  6. 5.2 Global Urinary Tract Infection Medications Sales by Application
  7. 5.2.1 Global Urinary Tract Infection Medications Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Urinary Tract Infection Medications Sales by Application (2021-2032)
  9. 5.2.3 Global Urinary Tract Infection Medications Sales Market Share by Application (2021-2032)
  10. 5.3 Global Urinary Tract Infection Medications Revenue by Application
  11. 5.3.1 Global Urinary Tract Infection Medications Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Urinary Tract Infection Medications Revenue by Application (2021-2032)
  13. 5.3.3 Global Urinary Tract Infection Medications Revenue Market Share by Application (2021-2032)
6 Global Urinary Tract Infection Medications Sales by Region
  1. 6.1 Global Urinary Tract Infection Medications Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Urinary Tract Infection Medications Sales by Region (2021-2032)
  3. 6.2.1 Global Urinary Tract Infection Medications Sales by Region (2021-2026)
  4. 6.2.2 Global Urinary Tract Infection Medications Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Urinary Tract Infection Medications Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Urinary Tract Infection Medications Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Urinary Tract Infection Medications Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Urinary Tract Infection Medications Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Urinary Tract Infection Medications Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Urinary Tract Infection Medications Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Urinary Tract Infection Medications Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Urinary Tract Infection Medications Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Urinary Tract Infection Medications Revenue by Region
  1. 7.1 Global Urinary Tract Infection Medications Revenue by Region
  2. 7.1.1 Global Urinary Tract Infection Medications Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Urinary Tract Infection Medications Revenue by Region (2021-2026)
  4. 7.1.3 Global Urinary Tract Infection Medications Revenue by Region (2027-2032)
  5. 7.1.4 Global Urinary Tract Infection Medications Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Urinary Tract Infection Medications Revenue (2021-2032)
  8. 7.2.2 North America Urinary Tract Infection Medications Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Urinary Tract Infection Medications Revenue (2021-2032)
  11. 7.3.2 Europe Urinary Tract Infection Medications Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Urinary Tract Infection Medications Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Urinary Tract Infection Medications Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Urinary Tract Infection Medications Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Urinary Tract Infection Medications Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Allecra Therapeutic
  2. 8.1.1 Allecra Therapeutic Company Information
  3. 8.1.2 Allecra Therapeutic Business Overview
  4. 8.1.3 Allecra Therapeutic Urinary Tract Infection Medications Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Allecra Therapeutic Urinary Tract Infection Medications Product Portfolio
  6. 8.1.5 Allecra Therapeutic Recent Developments
  7. 8.2 Bayer AG
  8. 8.2.1 Bayer AG Company Information
  9. 8.2.2 Bayer AG Business Overview
  10. 8.2.3 Bayer AG Urinary Tract Infection Medications Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Bayer AG Urinary Tract Infection Medications Product Portfolio
  12. 8.2.5 Bayer AG Recent Developments
  13. 8.3 Cipla Inc.
  14. 8.3.1 Cipla Inc. Company Information
  15. 8.3.2 Cipla Inc. Business Overview
  16. 8.3.3 Cipla Inc. Urinary Tract Infection Medications Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Cipla Inc. Urinary Tract Infection Medications Product Portfolio
  18. 8.3.5 Cipla Inc. Recent Developments
  19. 8.4 Eli Lily Company
  20. 8.4.1 Eli Lily Company Company Information
  21. 8.4.2 Eli Lily Company Business Overview
  22. 8.4.3 Eli Lily Company Urinary Tract Infection Medications Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Eli Lily Company Urinary Tract Infection Medications Product Portfolio
  24. 8.4.5 Eli Lily Company Recent Developments
  25. 8.5 GlaxoSmithKline plc
  26. 8.5.1 GlaxoSmithKline plc Company Information
  27. 8.5.2 GlaxoSmithKline plc Business Overview
  28. 8.5.3 GlaxoSmithKline plc Urinary Tract Infection Medications Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 GlaxoSmithKline plc Urinary Tract Infection Medications Product Portfolio
  30. 8.5.5 GlaxoSmithKline plc Recent Developments
  31. 8.6 MEDICE
  32. 8.6.1 MEDICE Company Information
  33. 8.6.2 MEDICE Business Overview
  34. 8.6.3 MEDICE Urinary Tract Infection Medications Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 MEDICE Urinary Tract Infection Medications Product Portfolio
  36. 8.6.5 MEDICE Recent Developments
  37. 8.7 Merck & Co. Inc.
  38. 8.7.1 Merck & Co. Inc. Company Information
  39. 8.7.2 Merck & Co. Inc. Business Overview
  40. 8.7.3 Merck & Co. Inc. Urinary Tract Infection Medications Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Merck & Co. Inc. Urinary Tract Infection Medications Product Portfolio
  42. 8.7.5 Merck & Co. Inc. Recent Developments
  43. 8.8 Novartis Ag
  44. 8.8.1 Novartis Ag Company Information
  45. 8.8.2 Novartis Ag Business Overview
  46. 8.8.3 Novartis Ag Urinary Tract Infection Medications Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Novartis Ag Urinary Tract Infection Medications Product Portfolio
  48. 8.8.5 Novartis Ag Recent Developments
  49. 8.9 Novo Nordisk A/S
  50. 8.9.1 Novo Nordisk A/S Company Information
  51. 8.9.2 Novo Nordisk A/S Business Overview
  52. 8.9.3 Novo Nordisk A/S Urinary Tract Infection Medications Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Novo Nordisk A/S Urinary Tract Infection Medications Product Portfolio
  54. 8.9.5 Novo Nordisk A/S Recent Developments
  55. 8.10 Utility Therapeutics
  56. 8.10.1 Utility Therapeutics Company Information
  57. 8.10.2 Utility Therapeutics Business Overview
  58. 8.10.3 Utility Therapeutics Urinary Tract Infection Medications Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Utility Therapeutics Urinary Tract Infection Medications Product Portfolio
  60. 8.10.5 Utility Therapeutics Recent Developments
  61. 8.11 Northeast Pharmaceuticals
  62. 8.11.1 Northeast Pharmaceuticals Company Information
  63. 8.11.2 Northeast Pharmaceuticals Business Overview
  64. 8.11.3 Northeast Pharmaceuticals Urinary Tract Infection Medications Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Northeast Pharmaceuticals Urinary Tract Infection Medications Product Portfolio
  66. 8.11.5 Northeast Pharmaceuticals Recent Developments
  67. 8.12 Guangxi Qingzhipin Pharmaceutical Co., Ltd.
  68. 8.12.1 Guangxi Qingzhipin Pharmaceutical Co., Ltd. Company Information
  69. 8.12.2 Guangxi Qingzhipin Pharmaceutical Co., Ltd. Business Overview
  70. 8.12.3 Guangxi Qingzhipin Pharmaceutical Co., Ltd. Urinary Tract Infection Medications Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Guangxi Qingzhipin Pharmaceutical Co., Ltd. Urinary Tract Infection Medications Product Portfolio
  72. 8.12.5 Guangxi Qingzhipin Pharmaceutical Co., Ltd. Recent Developments
  73. 8.13 Pfizer Inc.
  74. 8.13.1 Pfizer Inc. Company Information
  75. 8.13.2 Pfizer Inc. Business Overview
  76. 8.13.3 Pfizer Inc. Urinary Tract Infection Medications Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Pfizer Inc. Urinary Tract Infection Medications Product Portfolio
  78. 8.13.5 Pfizer Inc. Recent Developments
  79. 8.14 Teva Pharmaceuticals
  80. 8.14.1 Teva Pharmaceuticals Company Information
  81. 8.14.2 Teva Pharmaceuticals Business Overview
  82. 8.14.3 Teva Pharmaceuticals Urinary Tract Infection Medications Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Teva Pharmaceuticals Urinary Tract Infection Medications Product Portfolio
  84. 8.14.5 Teva Pharmaceuticals Recent Developments
  85. 8.15 Whiteson Pharma
  86. 8.15.1 Whiteson Pharma Company Information
  87. 8.15.2 Whiteson Pharma Business Overview
  88. 8.15.3 Whiteson Pharma Urinary Tract Infection Medications Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Whiteson Pharma Urinary Tract Infection Medications Product Portfolio
  90. 8.15.5 Whiteson Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Urinary Tract Infection Medications Value Chain Analysis
  2. 9.1.1 Urinary Tract Infection Medications Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Urinary Tract Infection Medications Production Mode & Process
  6. 9.2 Urinary Tract Infection Medications Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Urinary Tract Infection Medications Distributors
  9. 9.2.3 Urinary Tract Infection Medications Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst